Diarrhea on semaglutide
On this page
How common it was, and against what
A rate on its own says nothing, because people on placebo get diarrhea too. Both labels print the comparison, in populations that are not the same.
| Trial set | On the drug | On placebo |
|---|---|---|
| WEGOVY 2.4 mg, weight trials | 30% | 16% |
| OZEMPIC 0.5 mg, diabetes trials | 8.5% | 1.9% |
| OZEMPIC 1 mg, diabetes trials | 8.8% | 1.9% |
WEGOVY prescribing information, Table 3 (revised 6/2026): adults with obesity or overweight, 2.4 mg injection, N=2,116 against 1,261 on placebo. OZEMPIC prescribing information, Table 1 (revised 5/2026): adults with type 2 diabetes, N=260 and 261 against 262 on placebo. Both read September 2026 and listed under Sources.
The gap between the two labels is a gap between trials, not a fact about the molecule: different doses, different people, different lengths. What both agree on is direction — more than placebo, every time.1,2
When it turns up
Not evenly across treatment. Both labels put it in the same stretch, and OZEMPIC’s says so in one line:
The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation.
The escalation is sixteen weeks on WEGOVY’s schedule and four steps on OZEMPIC’s, so the stretch to plan around is the first few months and each new step inside it. The WEGOVY dose schedule and the OZEMPIC one set out where the steps fall.1,2
How long a bout lasts
In the pooled analysis of the 2.4 mg trials, the median episode of diarrhea ran three days, against eight for nausea and two for vomiting. Median means half of episodes were shorter and half longer, and the authors summarize that participants typically recovered from each event within a few days.3
Constipation is the exception to that pattern, and it is a longer story: constipation on semaglutide has it. The week-by-week shape for all four effects is on the duration page.
The warning that attaches to it
This is the part worth reading twice, because it is the reason diarrhea on this drug is not only an inconvenience:
The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.
The events in that sentence are postmarketing reports of acute kidney injury, in some cases requiring hemodialysis. The label’s instruction to prescribers is to monitor kidney function in patients reporting reactions that could lead to volume depletion, especially during initiation and escalation. In plain terms: the risk runs through fluid, and the fluid goes out fastest in exactly the weeks when this is most likely.1
The label also counts the severe end separately. Severe gastrointestinal reactions were reported in 4.1% of people on WEGOVY injection against 0.9% on placebo, and in 2% of people on the tablets against 0%.1
Questions
How long does diarrhea on semaglutide last?
In the pooled 2.4 mg trials the median episode ran three days, meaning half were shorter and half longer, and the authors report people typically recovered from each event within a few days.3
Is it worse after a dose increase?
When should I call someone about it?
The label’s own reason to take it seriously is dehydration: it reports postmarketing cases of acute kidney injury, most of them in patients whose gastrointestinal reactions led to dehydration, and it tells prescribers to monitor kidney function during initiation and escalation. Diarrhea you cannot stay ahead of belongs in a phone call rather than a search.1
Read next
Sources
A reference, not medical advice, and not a substitute for your prescriber or pharmacist. If you think you are having a medical emergency, call your local emergency number.